Literature DB >> 8228365

Cerebrospinal fluid neopterin concentrations in central nervous system infection.

L Hagberg1, L Dotevall, G Norkrans, M Larsson, H Wachter, D Fuchs.   

Abstract

Cerebrospinal fluid (CSF) neopterin levels were determined by RIA in individuals with central nervous system (CNS) or human immunodeficiency virus (HIV) infections and in healthy controls. The mean CSF neopterin concentrations were 63.0 nmol/L in 15 patients with acute bacterial meningitis, 54.9 nmol/L in 15 patients with Lyme neuroborreliosis, 32.5 nmol/L in 10 patients with viral meningitis, 130.9 nmol/L in 8 patients with viral encephalitis, 13.9 nmol/L in 15 patients with asymptomatic HIV infection, 26.0 nmol/L in 11 patients with AIDS without dementia, 65.4 nmol/L in 4 patients with AIDS dementia, and 4.2 nmol/L in 24 healthy controls. Although patients with viral encephalitis had higher mean neopterin levels than any other patient category studied, the CSF neopterin concentrations cannot be used to discriminate between viral and bacterial infections. Analysis of CSF levels of neopterin may be useful as guidance in following clinical course and effect of treatment and can provide information of value in addition to CSF cell count as a measurement of CNS immune stimulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228365     DOI: 10.1093/infdis/168.5.1285

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease.

Authors:  F Leblhuber; J Walli; G P Tilz; K Jellinger; H Wachter; D Fuchs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 2.  HIV-associated neurological disorders: a guide to pharmacotherapy.

Authors:  Ik L Tan; Justin C McArthur
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

3.  Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Authors:  Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

4.  Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels.

Authors:  L M Andersson; L Hagberg; D Fuchs; B Svennerholm; M Gisslén
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

5.  CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.

Authors:  Aurélien Viaccoz; François Ducray; Yannick Tholance; Gleicy Keli Barcelos; Laure Thomas-Maisonneuve; Hervé Ghesquières; David Meyronet; Isabelle Quadrio; Stéphanie Cartalat-Carel; Guy Louis-Tisserand; Emmanuel Jouanneau; Jacques Guyotat; Jérôme Honnorat; Armand Perret-Liaudet
Journal:  Neuro Oncol       Date:  2015-05-25       Impact factor: 12.300

6.  Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells.

Authors:  Oscar D Cano; Gabriele Neurauter; Dietmar Fuchs; Gene M Shearer; Adriano Boasso
Journal:  Neurosci Lett       Date:  2008-04-18       Impact factor: 3.046

7.  Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.

Authors:  Lars Hagberg; Paola Cinque; Magnus Gisslen; Bruce J Brew; Serena Spudich; Arabella Bestetti; Richard W Price; Dietmar Fuchs
Journal:  AIDS Res Ther       Date:  2010-06-03       Impact factor: 2.250

8.  Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Authors:  Aylin Yilmaz; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

Review 9.  Antiretroviral therapy and central nervous system HIV type 1 infection.

Authors:  Richard W Price; Serena Spudich
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

10.  Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy.

Authors:  Aylin Yilmaz; Constantin T Yiannoutsos; Dietmar Fuchs; Richard W Price; Kathryn Crozier; Lars Hagberg; Serena Spudich; Magnus Gisslén
Journal:  J Neuroinflammation       Date:  2013-05-10       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.